The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Neurology,Dermatology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s10072-021-05373-1.pdf
Reference31 articles.
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395(10223):497–506
2. Ghajarzadeh M, Bonavita S (2020) Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Neurol Sci 41(9):2315–2316
3. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184–191
4. (https://www.msif.org/news/2020/02/10/thecoronavirus-and-ms-what-you-need-to-know/)
5. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S et al (2016) Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PloS one 11(1):e0147601
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study;BMC Neurology;2024-08-20
2. The lung-brain axis in multiple sclerosis: Mechanistic insights and future directions;Brain, Behavior, & Immunity - Health;2024-07
3. SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population;Multiple Sclerosis and Related Disorders;2024-06
4. Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx;2024-05-28
5. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3